Media headlines about TG Therapeutics (NASDAQ:TGTX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. TG Therapeutics earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.397147992679 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:

How to Become a New Pot Stock Millionaire

Several research analysts have weighed in on TGTX shares. ValuEngine raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. BidaskClub lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, April 10th. Zacks Investment Research lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 13th. HC Wainwright reissued a “buy” rating and set a $33.00 price objective on shares of TG Therapeutics in a report on Monday, January 8th. Finally, B. Riley reissued a “buy” rating and set a $21.50 price objective on shares of TG Therapeutics in a report on Wednesday, January 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $24.60.

NASDAQ TGTX opened at $13.15 on Tuesday. TG Therapeutics has a one year low of $7.25 and a one year high of $17.35. The stock has a market capitalization of $1,012.77, a PE ratio of -6.88 and a beta of 1.20.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.46) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.46). TG Therapeutics had a negative net margin of 77,945.40% and a negative return on equity of 145.58%. The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million. analysts anticipate that TG Therapeutics will post -1.68 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.dailypolitical.com/2018/04/17/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-tg-therapeutics-tgtx-stock-price.html.

About TG Therapeutics

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Insider Buying and Selling by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.